Seattle, WA

Good Therapeutics is an early-stage biotechnology company developing context-dependent protein drugs that sense biomarkers which trigger therapeutic activity. Good Therapeutics’ goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Early applications of the company’s approach may include oncology.

Good Therapeutics was acquired by Roche on September 7, 2022


© Copyright RiverVest® All Rights Reserved.